DBC1 promotes anoikis resistance of gastric cancer cells by regulating NF-κB activity.
By: Yongwei Huan, Deping Wu, Dayong Zhou, Bo Sun, Guoxin Li

Department of General Surgery, the 82nd Hospital of the PLA, Huai'an, P.R. China.
2015-3-02; doi: 10.3892/or.2015.4007
Abstract

Deleted in breast cancer 1 (DBC1) has been known to be overexpressed and serves as a poor prognostic indicator of several human cancers. In this study, we examined DBC1 expression in a total of 142 gastric cancer tissues by immunohistochemistry and revealed that DBC1 was overexpressed in gastric cancer and significantly associated with TNM stage and lymph node metastasis. The in vitro experiments showed that DBC1 expression correlated with the ability of anoikis resistance in gastric cancer cells, which has been defined as critical to metastasis. Furthermore, the results showed that the IKK-β/NF-κB signaling pathway was involved in the regulation of anoikis resistance by DBC1 in gastric cancer cells. Taken together, the results indicated that DBC1 promotes anoikis resistance in gastric cancer cells by regulating NF-κB activity and may thus be a new therapeutic target for preventing potential metastasis.





PMID:26035299






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements